<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865538</url>
  </required_header>
  <id_info>
    <org_study_id>RELENT-1</org_study_id>
    <nct_id>NCT02865538</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms</brief_title>
  <official_title>Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nerre Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nerre Therapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose
      study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will
      be investigated in 4 cohorts. Each cohort will comprise of 20 subjects. Subjects will be
      dosed for 14 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in physical exam, 12-lead ECGs, clinical laboratory assessments, vital signs; and adverse events (safety parameters)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the curve (AUC)</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum plasma concentration (Cmax)</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Half-life (tÂ½)</measure>
    <time_frame>Days 1, 7 and 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in frequency of moderate to severe hot flashes as measured using a paper diary</measure>
    <time_frame>Days 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hot flash average severity as measured using a paper diary</measure>
    <time_frame>Days 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hot flash severity score as measured using a paper diary</measure>
    <time_frame>Days 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in night time awakenings secondary to hot flashes as measured using a paper diary</measure>
    <time_frame>Days 7 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Luteinizing Hormone AUC 0-8 hours</measure>
    <time_frame>Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Post-menopausal Vasomotor Symptoms</condition>
  <arm_group>
    <arm_group_label>NT-814</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NT-814 to be administered as oral capsules, daily, for 14 days, up to 4 doses, 50mg, 100mg, 150mg, 200mg, ascending by cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NT-814 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to match NT-814 capsules administered orally, daily. Number of placebo capsules to match active dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT-814</intervention_name>
    <arm_group_label>NT-814</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for NT-814)</intervention_name>
    <arm_group_label>NT-814 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Post-menopausal female subjects experiencing frequent moderate to severe hot flashes.
        Menopause will be defined as:

          -  12 months of spontaneous amenorrhea;

          -  OR at least 6 weeks' post-surgical bilateral oophorectomy with or without
             hysterectomy.

        Key Exclusion Criteria:

          -  BMI &gt; 35kg/m2.

          -  Any active comorbid disease, ECG or laboratory result deemed by the investigator to be
             clinically significant and which could impact safety during study conduct or that
             could interfere with the study evaluation, procedures or completion.

          -  Use of prohibited medications defined in the protocol.

          -  Inability or unwillingness to comply with study procedures or requirements.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Nerre Therapeutics Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS/MRA (Miami Clinical Research)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Clinical Research Unit</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2016</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hot flashes</keyword>
  <keyword>Post-menopausal</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

